Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis

2008

Comparing Drug Eluting and Bare Metal Stents in Diabetic and Non-Diabetic Patients

Sample size: 14899 publication 10 minutes Evidence: high

Author Information

Author(s): Stettler Christoph, Allemann Sabin, Wandel Simon, Kastrati Adnan, Morice Marie Claude, Schömig Albert, Pfisterer Matthias E, Stone Gregg W, Leon Martin B, de Lezo José Suárez, Goy Jean-Jacques, Park Seung-Jung, Sabaté Manel, Suttorp Maarten J, Kelbaek Henning, Spaulding Christian, Menichelli Maurizio, Vermeersch Paul, Dirksen Maurits T, Cervinka Pavel, Carlo Marco De, Erglis Andrejs, Chechi Tania, Ortolani Paolo, Schalij Martin J, Diem Peter, Meier Bernhard, Windecker Stephan, Jüni Peter

Primary Institution: Institute of Social and Preventive Medicine, University of Bern

Hypothesis

To compare the effectiveness and safety of three types of stents (sirolimus eluting, paclitaxel eluting, and bare metal) in people with and without diabetes mellitus.

Conclusion

In trials that specified a duration of dual antiplatelet therapy of six months or more after stent implantation, drug eluting stents seemed safe and effective in people both with and without diabetes.

Supporting Evidence

Drug eluting stents were associated with a decrease in revascularisation rates compared with bare metal stents.
Trials with dual antiplatelet therapy for less than six months showed increased mortality risks.
Overall mortality rates were similar across stent types in trials with longer dual antiplatelet therapy.

Takeaway

This study looked at different types of heart stents and found that using drug eluting stents is safe and helps people with diabetes and without diabetes when they take their medicine for long enough.